MINNEAPOLIS, July 29, 2015 (GLOBE NEWSWIRE) -- BioSig Technologies (OTCQB:BSGM), a medical device company developing PURE EP(TM), a proprietary technology platform designed to improve the fidelity of clinical signals available for electrophysiology (EP) procedures, today announced it has signed a Sponsored Research Agreement with The Regents of The University of California at Los Angeles ("UCLA") to conduct preclinical evaluation of BioSig's PURE EP(TM) System in a ventricular tachycardia (VT) model.
Dr. Jason Bradfield, Director of the specialized program for cardiovascular technology innovation of the UCLA Cardiac Arrhythmia Center will be the Principal Investigator; the studies will focus on intracardiac and percutaneous epicardial mapping utilizing the PURE EP information system to explore the complex scar architecture that typically supports multiple morphologies of VT.
Jay Millerhagen, VP of Clinical Affairs for BioSig Technologies, Inc. stated, "BioSig is very pleased to expand our clinical relationship with UCLA to the field of ventricular arrhythmias. UCLA is an institution with an impressive track record of research in the field of cardiac electrophysiology, and specifically VT."
Dr. Kalyanam Shivkumar, Director Cardiac Arrhythmia Center and EP Programs said, "Catheter ablation of ventricular tachycardia is perhaps one of the most complex challenges in interventional cardiology and new technologies are needed."
About BioSig Technologies
BioSig Technologies is a medical device company that is developing a proprietary technology platform designed to improve the $3 billion electrophysiology (EP) marketplace(1) (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP System.
PURE EP System is a surface electrocardiogram and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and providing clarity of data which may be used to guide the EP's in identifying ablation targets - areas of tissue to treat that otherwise create a heart rhythm disturbance (arrhythmia).
Analysts forecast the global market for EP devices will grow at a 12.1 percent compound annual growth rate, from $2.5 billion in 2012 to $5.5 billion by 2019(1) - making it one of the fastest growing medical device segments. Just in the US, the number of Atrial Fibrillation (AF) and Ventricular Tachycardia (VT) arrhythmia ablations is forecast to grow at 10.5 percent from 2012 to 2017(2).
BioSig intends to seek FDA 510(k) clearance for the PURE EP System. The Company has achieved proof of concept through UCLA labs and has performed preclinical studies at the Mayo Clinic in Minnesota. The Company is collaborating with several of the nation's most prestigious cardiac arrhythmia centers including Texas Cardiac Arrhythmia Institute, UCLA Cardiac Arrhythmia Center, and Mayo Clinic.
(1) Electrophysiology Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
(2) HRI 2013 "Global Opportunities in Medical Devices & Diagnostics" report; triangulation of multiple sources; *AF includes left atrial tachycardia, left WPW, left atrial flutter.
CONTACT: Investor Relations: Brian McLaughlin BioSig Technologies, Inc. firstname.lastname@example.org 917-370-9817
Source:BioSig Technologies, Inc.